Vimarsana
Biggest News Aggregation in the World

Page 44 - Merck Sharp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Merck Sharp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Merck Sharp Today - Breaking & Trending Today

Obtaining patent term extensions in Europe - Vimarsana News

Obtaining patent term extensions in Europe

IAM is a unique and timely intelligence service that treats IP as a business asset and tool rather than simply as a legal right, informing boardrooms worldwide.

Precision Medicine Takes Individual Approach to Diabetes - Vimarsana News

Precision Medicine Takes Individual Approach to Diabetes

The second international American Diabetes Association/European Association for the Study of Diabetes report seeks to improve diabetes prevention and care with an individual focus.

Clinical Trial: Tucatinib Plus Trastuzumab and Pertuzumab for HER2+ Advanced Breast Cancer - Vimarsana News

Clinical Trial: Tucatinib Plus Trastuzumab and Pertuzumab for HER2+ Advanced Breast Cancer

Researchers are testing the effects of adding tucatinib to trastuzumab and pertuzumab maintenance in patients with HER2+ advanced breast cancer.

Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study - Vimarsana News

Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study

Thomas Callender and colleagues present a development and validation study using parsimonious ensemble machine learning models to assess eligibility for lung cancer screening.

Source: plos.org
COVID-19 Therapeutics for Nonhospitalized Patients—Updates and Future Directions | Clinical Pharmacy and Pharmacology | JAMA - Vimarsana News

COVID-19 Therapeutics for Nonhospitalized Patients—Updates and Future Directions | Clinical Pharmacy and Pharmacology | JAMA

In this Viewpoint, the authors summarize the therapeutic landscape for COVID-19, discuss who is most likely to benefit from treatment, provide an update on mana